S&P 500 7,444 +0.44% Nasdaq 25,185 +0.84% Dow Jones 52,234 +0.55% FTSE 100 10,870 +1.24% DAX 25,628 +2.11% Nikkei 225 64,362 -0.88% Hang Seng 25,884 +3.69% WTI Crude 85.44 +3.43% Gold 4,098 +0.57% US 10-Year Treasury Yield 4.725 +1.81% S&P 500 7,444 +0.44% Nasdaq 25,185 +0.84% Dow Jones 52,234 +0.55% FTSE 100 10,870 +1.24% DAX 25,628 +2.11% Nikkei 225 64,362 -0.88% Hang Seng 25,884 +3.69% WTI Crude 85.44 +3.43% Gold 4,098 +0.57% US 10-Year Treasury Yield 4.725 +1.81%

LATEST

Bloomberg again defers decision on including Indian government bonds in Global Aggregate Index●Amazon’s stock rides booming cloud growth toward best day in 11 years●Jio Financial Services declares record date to finalise eligible shareholders for FY26 final dividend●SpaceX turns heads ahead of earnings with new mega deal●Auto components player Kay Jay Forgings, power infra EPC Polite Powertech get Sebi nod for IPOs●Guardant Health, Stock Of The Day, Spikes After Hiking 2026 Outlook●Inside Project Peregrine: Why Blackstone and KKR Bought Into Kuwait’s Oil Pipelines●Study Finds That A $1.2 Million Retirement and a $4 Million Retirement Look Almost Identical In Terms Of Spending●Bloomberg again defers decision on including Indian government bonds in Global Aggregate Index●Amazon’s stock rides booming cloud growth toward best day in 11 years●Jio Financial Services declares record date to finalise eligible shareholders for FY26 final dividend●SpaceX turns heads ahead of earnings with new mega deal●Auto components player Kay Jay Forgings, power infra EPC Polite Powertech get Sebi nod for IPOs●Guardant Health, Stock Of The Day, Spikes After Hiking 2026 Outlook●Inside Project Peregrine: Why Blackstone and KKR Bought Into Kuwait’s Oil Pipelines●Study Finds That A $1.2 Million Retirement and a $4 Million Retirement Look Almost Identical In Terms Of Spending●

Wealth

Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes

MarketWatch.com - Top Stories · 1h ago

Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes

The Danish healthcare company’s stock slumped on Friday after it announced the Phase 3 trial failure.

Read the full story at MarketWatch.com - Top Stories →

More Wealth

Amazon’s stock rides booming cloud growth toward best day in 11 years

MarketWatch.com - Top Stories · 29m ago

Here’s what’s worth streaming in August 2026 on Netflix, Hulu, HBO Max and more

MarketWatch.com - Top Stories · 55m ago

Apple heads for $460 billion wipeout with its stock seeing worst post-earnings drop in 13 years

MarketWatch.com - Top Stories · 1h ago

Is spending thousands of dollars on an AI certification worth it? Here’s how to decide.

MarketWatch.com - Top Stories · 1h ago